Neurosciences encompasses a broad range of research from the molecular (e.g. aptamer research) to clinical (e.g. research into concussion from sports).
Our goal is to be internationally recognized in 3 areas (neuro-oncology, dementia and neurodegeneration and molecular psychiatry). We have a bench to bedside approach capitalizing on our quite unique staff profile ranging from basic biomedical scientists through pharmaceutics to clinicians.
We also focus on collaborations with our local charities and a network of researchers and clinicians across the world.
We have a significant local impact in our neuro-oncology research. One strand of our Molecular Psychiatry group is research into legal highs and this research has had an impact on the government drug policy. Our Dementia and Neurodegeneration group is funded by the company.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
23
Jun 2026
A night without sleep produced increased markers of connections between brain cells, showing that sleep in humans may be important for restoring cellular balance in the brain, according to a study published June 23rd in the open access journal PLOS Biology by David Elmenhorst from the Forschungszentrum Jülich Institute of Neuroscience and Medicine in North Rhine-Westphalia, Germany, and colleagues.
23
Jun 2026
New Rutgers research suggests much of the seemingly endless waiting for complex medical care can be engineered away by recreating operations inside a computer and testing countless possible improvements.
23
Jun 2026
Using artificial intelligence (AI), researchers found that image-based risk scores for breast cancer derived from screening mammograms evolve over time and differ between women who develop cancer and those who do not, opening the door to a new era of dynamic breast cancer risk assessment.
23
Jun 2026
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract, with KIT mutations driving approximately 75% to 80% of cases.